Preview

Rational Pharmacotherapy in Cardiology

Advanced search

THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE

https://doi.org/10.20996/1819-6446-2016-12-2-220-226

Full Text:

Abstract

New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin (dabigatran), today are increasingly replacing warfarin and other indirect anticoagulants in preventing stroke in patients with non-valvular atrial fibrillation. They were superior to warfarin for some indicators of efficacy and safety in randomized controlled trials. However, the experience of their study in real clinical practice is limited. The need in prospective, observational studies is dictated by the fact that usual practice differs from the conditions of the randomized clinical trials that may improve the efficiency and safety of the treatment, including the expense of strict criteria for patient selection, regular visits, constant safety monitoring and etc. The results of prospective observational XANTUS study and retrospective cohort studies that shown similar results of treatment with new oral anticoagulants in randomized clinical trials and routine clinical practice are presented in the review.

About the Author

S. V. Moiseev
I.M. Sechenov First Moscow State Medical University, Moscow; M.V. Lomonosov Moscow State University , Moscow
Russian Federation


References

1. Haim M, Hoshen M, Reges O, et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc 2015;4:e001486.

2. Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Europ Heart J 2012;33,2719-47.

3. Yavelov IS, Moiseev SV. Antithrombotic therapy in current guidelines for the treatment of atrial fibrillation. Klinicheskaya Farmakologiya i Terapiya 2011; 20 (3): 64-70. In Russian (Явелов И.С., Моисеев С.В. Антитромботическая терапия в современных рекомендациях по лечению фибрилляции предсердий. Клиническая Фармакология и Терапия 2011;20(3):64-70).

4. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Еuro Нeart Survey on atrial fibrillation. Chest 2010;137(2):263-72.

5. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146(12):857-67.

6. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:e1-e76.

7. Huisman MV, Rothman KJ, Paquette M, et al. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. Am J Med 2015;128(12):1306-13.

8. Kakkar AK, Mueller I, Bassand J-P, et al. Risk profiles and antithrombotic treatment of patients wewly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD Registry. PLoS ONE 2013;8(5):e63479.

9. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91.

10. Hankey G, Patel M, Stevens S, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012;11(4):315-22.

11. Moiseyev VS, Tcheltsov VV. The modern view of prevention insulthat in atrial fibrillation: study ROCKET AF and J-ROCKET AF. Klinicheskaya Farmakologiya i Terapiya 2012; 21 (3): 32-8. In Russian (Моисеев В.С., Чельцов В.В. Современный взгляд на профилактику инсульта при фибрилляции предсердий: исследования ROCKET AF и J-ROCKET AF. Клиническая Фармакология и Терапия 2012;21(3):32-8).

12. Camm AJ, Amarenco P, Haas S, et al., on behalf of the XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016;37(14):1145-53.

13. Connolly SJ, Ezekowitz MD, Yusuf S, et al, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.

14. Granger CB, Alexander JH, McMurray JJ, et al, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.

15. Gomes T, Mamdani MM, Holbrook AM, et al. Persistence with therapy among patients treated with warfarin for atrial fibrillation. Arch Intern Med 2012;172:1687-9.

16. Song X, Sander SD, Varker H, Amin A. Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation. Am J Cardiovasc Drugs 2012;12:245-53.

17. Bushnell CD, Olson DM, Zhao X, et al. Secondary preventive medication persistence and adherence 1year after stroke. Neurology 2011;77:1182-90.

18. Simons LA, Ortiz M, Germanos P, Calcino G. Persistence on warfarin in patients with atrial fibrillation: experience in Australia 2006-2009. Australian Family Physician 2013;42(9):659-61.

19. Moiseev SV Adherence to anticoagulant therapy: problems and solutions. Klinicheskaya Farmakologiya i Terapiya 2014; 23 (4): 23-8. In Russian (Моисеев С.В. Приверженность к антикоагулянтной терапии: проблемы и пути решения. Клиническая Фармакология и Терапия 2014;23(4):23-8).

20. Zamorano JL, Greiner W, Sandberg A, et al. Patient preferences for chronic treatment for stroke prevention: results from the European Patients survey in Atrial Fibrillation (EUPS-AF). Annual Congress of the European Society of Cardiology, Munich, August 26th, 2012.

21. Coleman CI, Roberts MS, Sobieraj DM, et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 2012;28(5):669-80.

22. McHorney CA, Crivera C, Laliberté F, et al. Adherence to non-VKA oral anticoagulant medications based on the pharmacy quality alliance measure. Curr Med Res Opin 2015; 22:1-7.

23. Beyer-Westendorf J, Förster K, Ebertz F, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace 2015;17(4):530-8.

24. Hecker J, Marten S, Keller L, et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost 2016; 115. doi.org/10.1160/TH15-10-0840.

25. Tamayo S, Peacock F, Patel M, et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol 2015;38(2):63-8.

26. Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: A nationwide cohort study. Amer J Med 2014;127:1172-8.

27. Sorensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open 2013;3:e002758.

28. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131(2):157-64.

29. Artang R, Rome E, Nielsen JD, Vidaillet HJ. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol 2013;112(12): 1973-9.

30. Hernandez I, Baik SH, Piñera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2015;175(1):18-24.

31. Moiseev SV, Kiyakbaev GG, Fomin VV. New oral anticoagulants in the prevention of stroke in patients with atrial fibrillation and chronic kidney disease. Klinicheskaya Farmakologiya i Terapiya 2015; 24 (3): 5-11. In Russian (Моисеев С.В., Киякбаев Г.Г., Фомин В.В. Новые пероральные антикоагулянты в профилактике инсульта у больных с фибрилляцией предсердий и хронической болезнью почек. Клиническая Фармакология и Терапия 2015;24(3):5-11).

32. Chang HY, Zhou M, Tang W, et al. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ 2015;350:h1585.

33. Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015;350:h1857.


For citation:


Moiseev S.V. THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology. 2016;12(2):220-226. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-2-220-226

Views: 433


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)